CancerDrs

Prostate Cancer clinical trials in Louisiana

19 actively recruiting prostate cancer trials at 10 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Louisiana:
  • Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
  • Mary Bird Perkins Cancer Center - Gonzales — Gonzales, Louisiana
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Louisiana:
  • Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
  • Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
  • Mary Bird Perkins Cancer Center - Metairie — Metairie, Louisiana
  • University Medical Center New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Louisiana:
  • East Jefferson General Hospital — Metairie, Louisiana
  • LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Louisiana:
  • East Jefferson General Hospital — Metairie, Louisiana
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Louisiana:
  • East Jefferson General Hospital — Metairie, Louisiana
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Louisiana:
  • Ochsner Clinic Foundation ( Site 0108) — New Orleans, Louisiana
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Louisiana:
  • Hematology/Oncology Clinic PLLC — Baton Rouge, Louisiana
  • Ochsner High Grove — Baton Rouge, Louisiana
  • Ochsner Medical Center Kenner — Kenner, Louisiana
  • East Jefferson General Hospital — Metairie, Louisiana
  • LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
Phase 2 Recruiting Industry

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …

Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Louisiana:
  • East Jefferson General Hospital Metairie — New Orleans, Louisiana
Phase 2 Recruiting Industry

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Louisiana:
  • Ochsner Health - Ochsner Medical Center - New Orleans — New Orleans, Louisiana
Phase 1 Recruiting Industry

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor,…

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06784193
Sites in Louisiana:
  • University Medical Center - New Orleans — New Orleans, Louisiana
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
  • Our Lady of The Lake — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana:
  • Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Recruiting Academic/Other

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 C…

Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT03151629
Sites in Louisiana:
  • Tulane University — New Orleans, Louisiana
Phase 4 Recruiting Industry

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in Louisiana:
  • Tulane Cancer Center — New Orleans, Louisiana
  • Ochsner Clinic Foundation — New Orleans, Louisiana

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15